Arturo Cesaro

University of Campania "Luigi Vanvitelli" — Italy

Medicine · Health Sciences

32h-index3.2kcitations158works6.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lipoproteins and Cardiovascular Health(32), Antiplatelet Therapy and Cardiovascular Diseases(30), Coronary Interventions and Diagnostics(19), Acute Myocardial Infarction Research(19), Diabetes Treatment and Management(19)

Publications158 total

Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention
Journal of Clinical Medicine·2025· 1 citedOpen Access
Vitamin D and Cardiovascular Disease: The “Good”, the “Bad”, and the “Unknown”
Reviews in Cardiovascular Medicine·2025Open Access
Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy
Journal of clinical lipidology·2025· 2 citedOpen Access
Feature Reviews in Cardiovascular Diseases
Biomedicines·2025Open Access
P2Y12 Inhibitor Monotherapy in Coronary Artery Disease: Translating Evidence Into Practice
Reviews in Cardiovascular Medicine·2025Open Access
Lung ultrasound in cardiac rehabilitation: expert consensus on protocols, clinical use, and integration into patient management from the working group on cardiac rehabilitation and cardiovascular prevention of the Italian society of cardiology
Heart Failure Reviews·2025· 2 citedOpen Access
Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
Journal of the American College of Cardiology·2025· 10 cited
Weight for rhythm: is the evidence for atrial fibrillation risk with semaglutide still premature?: reply
European Journal of Preventive Cardiology·2025Open Access
Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study
Pharmaceuticals·2025· 1 citedOpen Access
Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions
Expert Review of Cardiovascular Therapy·2025· 2 cited
Lipoproteina(a) e rischio cardiovascolare: una roadmap per la gestione del paziente. Documento congiunto della Società Italiana per lo studio dell'Aterosclerosi (SISA), della Società Italiana di Cardiologia (SIC), della Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) e di SIBioC
Biochimica Clinica·2025
Position paper ANMCO in collaborazione con ITACARE-P: Gestione della dimissione ospedaliera
Giornale italiano di cardiologia·2025
Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis
Journal of the American Heart Association·2025· 3 citedOpen Access
Comprehensive insights into peripheral artery disease: an overview from the working groups of pathogenesis of atherosclerosis and thrombosis of the Italian Society of Cardiology
Journal of Cardiovascular Medicine·2025· 1 cited
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Journal of Clinical Medicine·2025Open Access
Reply to ‘Oral formulation and SGLT2i interaction: key nuances in semaglutide’s effect on atrial fibrillation’
European Journal of Preventive Cardiology·2025· 1 cited
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials
European Journal of Preventive Cardiology·2025· 17 citedOpen Access
Do Beta-Blockers Really Matter in Patients with Myocardial Infarction Without Left Ventricular Systolic Dysfunction? Comment on Sabina et al. Beta-Blockers in Patients with Myocardial Infarction and Preserved Left Ventricular Ejection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med. 2025, 14, 150
Journal of Clinical Medicine·2025· 2 citedOpen Access
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain
European Heart Journal - Cardiovascular Pharmacotherapy·2025· 1 citedOpen Access
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy
High Blood Pressure & Cardiovascular Prevention·2025· 5 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Paolo Calabrò(47), Felice Gragnano(30), Fabio Fimiani(22), Elisabetta Moscarella(22), Giuseppe Limongelli(18), Celestino Sardu(10), Raffaele Marfella(10), Olga Scudiero(8), Ferdinando Carlo Sasso(8), Ciro Mauro(7), Martina Caiazza(7), Laura D’Erasmo(7), Marcello Arca(7), Francesco Natale(6), Claudia Concilio(6), Emanuele Monda(6), Giuseppe Patti(6), Ciro Indolfi(6), Cristina Mazzaccara(6), Barbara Lombardo(6)